Project description:Information about how different forms of CMT affect children is not readily available because there are not good methods to measure impairment of children with CMT. The purpose of this project is to develop and test such a method and to then test this scale to ensure that it is an effective measurement of impairment of CMT in children, that the children tolerate it well, that different investigators using this method obtain similar results and that changes over time with the scale allow measurement of progression of CMT in the children. Primary Objective: To develop and test the CMT Peds scale (CMTPedS) in children with CMT in order to refine the scoring for future natural history and therapeutic trials. Secondary Objective: We propose to test the sensitivity of the CMT Peds Scale in a longitudinal study and compare the CMT Peds Scale with the Children's Quality of Life scale CHQ-PF50. 2000 patients <21 years of age with various forms of CMT will be evaluated at baseline and at subsequent annual follow up visits when possible. This first study release makes available data of n=208 study participants.

| phs001553 | dbGaP

Development and Validation of a Disability Severity Index for Charcot-Marie-Tooth Disease (CMT) - INC 6604

Project description:Development and Validation of a Disability Severity Index for Charcot-Marie-Tooth Disease (CMT) - INC 6604

| PRJNA374388 | ENA

Development of a Large-Scale Chemogenomics Database to Improve Drug Candidate Selection

Project description:Development of a Large-Scale Chemogenomics Database to Improve Drug Candidate Selection and to Understand Mechanisms of Chemical Toxicity and Action These data support the publication titled "Development of a Large-Scale Chemogenomics Database to Improve Drug Candidate Selection and to Understand Mechanisms of Chemical Toxicity and Action" Copyright (c) 2005 by Iconix Pharmaceuticals, Inc. Guidelines for commercial use: http://www.iconixbiosciences.com/guidelineCommUse.pdf Keywords: other

2005-06-01 | GSE2409 | GEO

Development of a Large-Scale Chemogenomics Database to Improve Drug Candidate Selection

2005-05-31 | E-GEOD-2409 | biostudies-arrayexpress

Key regulators in two different colorectal cancer cell lines 1638N-T1 vs. CMT-93

Project description:In this dataset, we present RNA-Seq data of two colorectal cancer (CRC) cell lines, namely 1638N-T1 and CMT-93.

2016-12-02 | GSE78696 | GEO

INC-Seq

Project description:INC-Seq: Accurate single molecule reads using nanopore sequencing

| PRJEB12294 | ENA

RNA-sequencing data of CMT-93 cells exposed to LPS and/or garlic extract

Project description:We show here the transcriptional response in CMT-93 intestinal epithelial cells treated with Trichuris muris antigen and/or a garlic extract (40% PTSO-PTS).

2021-11-02 | GSE178655 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data